当前位置: 首页 >> 检索结果
721. Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement: Analysis of the PARTNER 2 Trials.
作者: Ariel Furer.;Shmuel Chen.;Bjorn Redfors.;Sammy Elmariah.;Philippe Pibarot.;Howard C Herrmann.;Rebecca T Hahn.;Susheel Kodali.;Vinod H Thourani.;Pamela S Douglas.;Maria C Alu.;William F Fearon.;Jonathan Passeri.;S Chris Malaisrie.;Aaron Crowley.;Thomas McAndrew.;Philippe Genereux.;Ori Ben-Yehuda.;Martin B Leon.;Daniel Burkhoff.
来源: Circ Heart Fail. 2019年12卷8期e005809页
Impaired left ventricular function is associated with worse prognosis among patients with aortic stenosis treated medically or with surgical aortic valve replacement. It is unclear whether reduced left ventricular ejection fraction (LVEF) is an independent predictor of adverse outcomes after transcatheter aortic valve replacement.
722. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
作者: Michael E Nassif.;Sheryl L Windsor.;Fengming Tang.;Yevgeniy Khariton.;Mansoor Husain.;Silvio E Inzucchi.;Darren K McGuire.;Bertram Pitt.;Benjamin M Scirica.;Bethany Austin.;Mark H Drazner.;Michael W Fong.;Michael M Givertz.;Robert A Gordon.;Rita Jermyn.;Stuart D Katz.;Sumant Lamba.;David E Lanfear.;Shane J LaRue.;JoAnn Lindenfeld.;Michael Malone.;Kenneth Margulies.;Robert J Mentz.;R Kannan Mutharasan.;Michael Pursley.;Guillermo Umpierrez.;Mikhail Kosiborod.
来源: Circulation. 2019年140卷18期1463-1476页
Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established HF with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remain unknown.
723. Dynamic Changes in the Molecular Signature of Adverse Left Ventricular Remodeling in Patients With Compensated and Decompensated Chronic Primary Mitral Regurgitation.
作者: Keir McCutcheon.;Caroline Dickens.;Jos van Pelt.;Therese Dix-Peek.;Sacha Grinter.;Lindsay McCutcheon.;Atulkumar Patel.;Martin Hale.;Nqoba Tsabedze.;Ahmed Vachiat.;Don Zachariah.;Raquel Duarte.;Stefan Janssens.;Pravin Manga.
来源: Circ Heart Fail. 2019年12卷9期e005974页
There is no proven medical therapy that attenuates adverse left ventricular remodeling in patients with chronic primary mitral regurgitation (CPMR). Identification of molecular pathways important in the progression of left ventricular remodeling in patients with CPMR may lead to development of new therapeutic strategies.
724. Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
作者: John W Eikelboom.;Stuart J Connolly.;Jacqueline Bosch.;Olga Shestakovska.;Victor Aboyans.;Marco Alings.;Sonia S Anand.;Alvaro Avezum.;Scott D Berkowitz.;Deepak L Bhatt.;Nancy Cook-Bruns.;Camilo Felix.;Keith A A Fox.;Robert G Hart.;Aldo P Maggioni.;Paul Moayyedi.;Martin O'Donnell.;Lars Rydén.;Peter Verhamme.;Petr Widimsky.;Jun Zhu.;Salim Yusuf.
来源: Circulation. 2019年140卷18期1451-1459页
Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be the first manifestation of underlying cancer.
725. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
作者: Senthil Selvaraj.;Brian Claggett.;Andrea Pozzi.;John J V McMurray.;Pardeep S Jhund.;Milton Packer.;Akshay S Desai.;Eldrin F Lewis.;Muthiah Vaduganathan.;Martin P Lefkowitz.;Jean L Rouleau.;Victor C Shi.;Michael R Zile.;Karl Swedberg.;Scott D Solomon.
来源: Circulation. 2019年140卷17期1369-1379页
The contemporary prognostic value of the physical examination- beyond traditional risk factors including natriuretic peptides, risk scores, and symptoms-in heart failure (HF) with reduced ejection fraction is unknown. We aimed to determine the association between physical signs of congestion at baseline and during study follow-up with quality of life and clinical outcomes and to assess the treatment effects of sacubitril/valsartan on congestion.
726. Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure.
作者: Marie Bayer Elming.;Anna M Thøgersen.;Lars Videbæk.;Niels E Bruun.;Hans Eiskjær.;Jens Haarbo.;Kenneth Egstrup.;Finn Gustafsson.;Jesper Hastrup Svendsen.;Dan E Høfsten.;Steen Pehrson.;Jens C Nielsen.;Lars Køber.;Jens Jakob Thune.
来源: Circ Heart Fail. 2019年12卷9期e006022页
Patients with nonischemic systolic heart failure (HF) have increased risk of sudden cardiac death (SCD) and death from progressive pump failure. Whether the risk of SCD changes over time is unknown. We seek here to investigate the relation between duration of HF, mode of death, and effect of implantable cardioverter-defibrillator implantation.
727. Left Main Coronary Artery Disease Revascularization According to the SYNTAX Score.
作者: Evan Shlofmitz.;Philippe Généreux.;Shmuel Chen.;Ovidiu Dressler.;Ori Ben-Yehuda.;Marie-Claude Morice.;John D Puskas.;David P Taggart.;David E Kandzari.;Aaron Crowley.;Björn Redfors.;Ghazaleh Mehdipoor.;Arie Pieter Kappetein.;Joseph F Sabik.;Patrick W Serruys.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2019年12卷9期e008007页
The SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score (SS), a measure of anatomic coronary artery disease (CAD) extent and complexity, has proven useful in past studies to determine the absolute and relative prognosis after revascularization with percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG). We sought to assess contemporary outcomes after PCI and CABG in patients with left main CAD according to SS and revascularization type from a large randomized trial.
728. A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes: The Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High-Sensitivity Troponin T Study (RAPID-TnT).
作者: Derek P Chew.;Kristina Lambrakis.;Andrew Blyth.;Anil Seshadri.;Michael J R Edmonds.;Tom Briffa.;Louise A Cullen.;Stephen Quinn.;Jonathan Karnon.;Anthony Chuang.;Adam J Nelson.;Deborah Wright.;Matthew Horsfall.;Erin Morton.;John K French.;Cynthia Papendick.
来源: Circulation. 2019年140卷19期1543-1556页
High-sensitivity troponin assays promise earlier discrimination of myocardial infarction. Yet, the benefits and harms of this improved discriminatory performance when incorporated within rapid testing protocols, with respect to subsequent testing and clinical events, has not been evaluated in an in-practice patient-level randomized study. This multicenter study evaluated the noninferiority of a 0/1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol in comparison with a 0/3-hour masked hs-cTnT protocol in patients with suspected acute coronary syndrome presenting to the emergency department (ED).
729. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
作者: Matthew T Roe.;Qian H Li.;Deepak L Bhatt.;Vera A Bittner.;Rafael Diaz.;Shaun G Goodman.;Robert A Harrington.;J Wouter Jukema.;Patricio Lopez-Jaramillo.;Renato D Lopes.;Michael J Louie.;Patrick M Moriarty.;Michael Szarek.;Robert Vogel.;Harvey D White.;Andreas M Zeiher.;Marie T Baccara-Dinet.;Ph Gabriel Steg.;Gregory G Schwartz.
来源: Circulation. 2019年140卷19期1578-1589页
The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non-high-density lipoprotein cholesterol ≥100 mg/dL despite maximum tolerated statin therapy. Such patients are considered at very high risk (VHR) based on a history of >1 major atherosclerotic cardiovascular disease (ASCVD) event or a single ASCVD event and multiple high-risk conditions. We investigated the association of US guideline-defined risk categories with the occurrence of ischemic events after acute coronary syndrome and reduction of those events by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor.
730. Effects of Mobile Text Messaging on Glycemic Control in Patients With Coronary Heart Disease and Diabetes Mellitus: A Randomized Clinical Trial.
作者: Xiqian Huo.;Harlan M Krumholz.;Xueke Bai.;Erica S Spatz.;Qinglan Ding.;Paul Horak.;Weigang Zhao.;Qiuhong Gong.;Haibo Zhang.;Xiaofang Yan.;Ying Sun.;Jiamin Liu.;Xuekun Wu.;Wenchi Guan.;Xiuling Wang.;Jing Li.;Xi Li.;John A Spertus.;Frederick A Masoudi.;Xin Zheng.
来源: Circ Cardiovasc Qual Outcomes. 2019年12卷9期e005805页
Mobile health interventions may support risk factor management and are readily scalable in healthcare systems. We aim to evaluate the efficacy of a text messaging-based intervention to improve glycemic control in patients with coronary heart disease and diabetes mellitus in China.
731. Internal Versus External Electrical Cardioversion of Atrial Arrhythmia in Patients With Implantable Cardioverter-Defibrillator: A Randomized Clinical Trial.
作者: Jakob Lüker.;Kathrin Kuhr.;Arian Sultan.;Georg Nölker.;Hazem Omran.;Stephan Willems.;René Andrié.;Jan W Schrickel.;Stefan Winter.;Dirk Vollmann.;Roland R Tilz.;Alexander Jobs.;Christian-H Heeger.;Andreas Metzner.;Sven Meyer.;Karl Mischke.;Andreas Napp.;Andreas Fahrig.;Susanne Steinhauser.;Johannes Brachmann.;Stephan Baldus.;Rajiv Mahajan.;Prashanthan Sanders.;Daniel Steven.
来源: Circulation. 2019年140卷13期1061-1069页
Atrial arrhythmias are common in patients with implantable cardioverter-defibrillator (ICD). External shocks and internal cardioversion through commanded ICD shock for electrical cardioversion are used for rhythm-control. However, there is a paucity of data on efficacy of external versus internal cardioversion and on the risk of lead and device malfunction. We hypothesized that external cardioversion is noninferior to internal cardioversion for safety, and superior for successful restoration of sinus rhythm.
732. Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents.
作者: Dean J Kereiakes.;Stephan Windecker.;R Lee Jobe.;Shamir R Mehta.;Ian J Sarembock.;Robert L Feldman.;Bernardo Stein.;Christophe Dubois.;Timothy Grady.;Shigeru Saito.;Takeshi Kimura.;Paul Underwood.;Dominic J Allocco.;Ian T Meredith.
来源: Circ Cardiovasc Interv. 2019年12卷9期e008152页
The thin-strut SYNERGY stent has an abluminal everolimus-eluting bioabsorbable polymer coating designed to facilitate vascular healing and reduce risk of stent thrombosis. In the multicenter, randomized EVOLVE II trial (The EVOLVE II Clinical Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion[s]), SYNERGY was noninferior to the durable polymer PROMUS Element Plus everolimus-eluting stent for the primary end point of 1-year target lesion failure. Longer-term clinical follow-up will support the relative efficacy and safety of SYNERGY.
733. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
作者: Subodh Verma.;C David Mazer.;Andrew T Yan.;Tamique Mason.;Vinay Garg.;Hwee Teoh.;Fei Zuo.;Adrian Quan.;Michael E Farkouh.;David H Fitchett.;Shaun G Goodman.;Ronald M Goldenberg.;Mohammed Al-Omran.;Richard E Gilbert.;Deepak L Bhatt.;Lawrence A Leiter.;Peter Jüni.;Bernard Zinman.;Kim A Connelly.
来源: Circulation. 2019年140卷21期1693-1702页
SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 diabetes mellitus and coronary artery disease.
734. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial.
作者: Yasuyoshi Ouchi.;Jun Sasaki.;Hidenori Arai.;Koutaro Yokote.;Kazumasa Harada.;Yasuo Katayama.;Takao Urabe.;Yasufumi Uchida.;Masaru Hayashi.;Naoto Yokota.;Hirokazu Nishida.;Takatoshi Otonari.;Tadashi Arai.;Ichiro Sakuma.;Kazuo Sakabe.;Masayasu Yamamoto.;Takashi Kobayashi.;Shinichi Oikawa.;Shizuya Yamashita.;Hiromi Rakugi.;Takumi Imai.;Shiro Tanaka.;Yasuo Ohashi.;Masanari Kuwabara.;Hideki Ito.
来源: Circulation. 2019年140卷12期992-1003页
Evidence regarding the primary prevention of coronary artery disease events by low-density lipoprotein cholesterol (LDL-C) lowering therapy in older individuals, aged ≥75 years, is insufficient. This trial tested whether LDL-C-lowering therapy with ezetimibe is useful for the primary prevention of cardiovascular events in older patients.
735. Ripple-AT Study: A Multicenter and Randomized Study Comparing 3D Mapping Techniques During Atrial Tachycardia Ablations.
作者: Vishal Luther.;Sharad Agarwal.;Anthony Chow.;Michael Koa-Wing.;Nuno Cortez-Dias.;Luís Carpinteiro.;João de Sousa.;Richard Balasubramaniam.;David Farwell.;Shahnaz Jamil-Copley.;Neil Srinivasan.;Hakam Abbas.;James Mason.;Nikki Jones.;George Katritsis.;Phang Boon Lim.;Nicholas S Peters.;Norman Qureshi.;Zachary Whinnett.;Nick W F Linton.;Prapa Kanagaratnam.
来源: Circ Arrhythm Electrophysiol. 2019年12卷8期e007394页
Ripple mapping (RM) is an alternative approach to activation mapping of atrial tachycardia (AT) that avoids electrogram annotation. We tested whether RM is superior to conventional annotation based local activation time (LAT) mapping for AT diagnosis in a randomized and multicenter study.
736. Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome.
作者: Matthew M Y Lee.;Mark C Petrie.;Paul Rocchiccioli.;Joanne Simpson.;Colette E Jackson.;David S Corcoran.;Kenneth Mangion.;Ammani Brown.;Pio Cialdella.;Novalia P Sidik.;Margaret B McEntegart.;Aadil Shaukat.;Alan P Rae.;Stuart H M Hood.;Eileen E Peat.;Iain N Findlay.;Clare L Murphy.;Alistair J Cormack.;Nikolay B Bukov.;Kanarath P Balachandran.;Keith G Oldroyd.;Ian Ford.;Olivia Wu.;Alex McConnachie.;Sarah J E Barry.;Colin Berry.; .
来源: Circ Cardiovasc Interv. 2019年12卷8期e007830页
The benefits of routine invasive management in patients with prior coronary artery bypass grafts presenting with non-ST elevation acute coronary syndromes are uncertain because these patients were excluded from pivotal trials.
737. Transcatheter Aortic Valve Replacement With the HLT Meridian Valve.
作者: Josep Rodés-Cabau.;Mathew R Williams.;Harindra C Wijeysundera.;Dean J Kereiakes.;Jean-Michel Paradis.;Cezar Staniloae.;Muhamed Saric.;Sam Radhakrishnan.;Robert F Wilson.;Spencer H Kubo.
来源: Circ Cardiovasc Interv. 2019年12卷8期e008053页
While most self-expanding transcatheter valves are repositionable, only one fully retrievable valve is currently available. The Meridian valve is a new self-expanding valve with full retrievability properties. The objective of our study was to evaluate the early feasibility, preliminary safety, and efficacy of transcatheter aortic valve replacement with the HLT Meridian valve (HLT, Inc).
738. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial.
作者: Brian A Bergmark.;Deepak L Bhatt.;Darren K McGuire.;Avivit Cahn.;Ofri Mosenzon.;Ph Gabriel Steg.;KyungAh Im.;Estella Kanevsky.;Yared Gurmu.;Itamar Raz.;Eugene Braunwald.;Benjamin M Scirica.; .
来源: Circulation. 2019年140卷12期1004-1014页
Metformin is first-line therapy for type 2 diabetes mellitus, although its effects on the cardiovascular system are unproved.
739. Donor Simvastatin Treatment in Heart Transplantation.
作者: Antti I Nykänen.;Emil J Holmström.;Raimo Tuuminen.;Rainer Krebs.;Kishor Dhaygude.;Matti Kankainen.;Janne J Jokinen.;Jyri Lommi.;Ilkka Helanterä.;Anne Räisänen-Sokolowski.;Simo O Syrjälä.;Karl B Lemström.
来源: Circulation. 2019年140卷8期627-640页
Ischemia-reperfusion injury may compromise the short-term and long-term prognosis after heart transplantation. Experimental studies show that simvastatin administered to the organ donor is vasculoprotective and inhibits cardiac allograft ischemia-reperfusion injury.
740. Comparison Between Contact Force Monitoring and Unipolar Signal Modification as a Guide for Catheter Ablation of Atrial Fibrillation: Prospective Multi-Center Randomized Study.
作者: Koichiro Ejima.;Ken Kato.;Ayako Okada.;Osamu Wakisaka.;Ryusuke Kimura.;Makoto Ishizawa.;Taku Imai.;Yuko Toyama.;Morio Shoda.;Nobuhisa Hagiwara.
来源: Circ Arrhythm Electrophysiol. 2019年12卷8期e007311页
Both contact force monitoring (CFM) and unipolar signal modification (USM) are guides for ablation, which improve the efficacy of pulmonary vein isolation of atrial fibrillation. We sought to compare the outcomes of atrial fibrillation ablation guided by CFM or USM.
|